Last reviewed · How we verify
A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D CAR-T cells in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy.
Details
| Lead sponsor | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China |
|---|---|
| Phase | NA |
| Status | RECRUITING |
| Enrolment | 10 |
| Start date | 2024-07-01 |
| Completion | 2026-12 |
Conditions
- Relapsed/Refractory Multiple Myeloma
Interventions
- Anti-BCMA-GPRC5D CAR-T cells infusion
Primary outcomes
- Incidence of adverse events(AE) after infusion — within 2 years after infusion
The frequency, severity, and laboratory findings of all adverse events/serious adverse events are included.Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome are graded by American Society for Transplantation and Cellular Therapy (ASTCT) criteria.
Countries
China